DRDO provides license to Laurus Labs for manufacturing COVID drug 2-DG
Advertisement
Hyderabad: Hyderabad based Laurus Labs Limited has recently announced that the company has received the licence from Defence Research & Development Organisation (DRDO) to manufacture and market of 2- Deoxy-D-Glucose (2DG).
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country.
"Laurus Labs has already applied with CDSCO for emergency use authroisation (EUA) for 2DG," the company said.
Read also: Laurus Labs reports Rs 297 crore net profit in Q4
Laurus Labs is a research-driven pharmaceutical manufacturing and biotech company headquartered in Hyderabad, India.
The company's major focus areas include anti-retroviral, Hepatitis C and Oncology drugs.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.